Jefferson Revell, PhD

Principal Scientist at AstraZeneca

Speaker

I have been with AstraZeneca since 2008, helping to initiate and establish the peptide therapeutics platform in Cambridge. I trained in synthetic organic methodology, later specialising in peptide chemistry, and have worked broadly across several R&D therapeutic areas, co-leading projects in metabolism, respiratory & inflammation, chronic pain, and most recently oncology targeted delivery. My research interests include design and development of high impact peptide drugs, innovations and technologies enabling oral peptide delivery, accessing and targeting the intracellular space, and the application of peptides in oncology, specifically radioconjugates.